RedHill Biopharma Ltd.
Stock Forecast, Prediction & Price Target

	Passed			Analyst forecast
Metric	12/31/2021	12/31/2022	12/31/2023	12/31/2025	12/31/2026
Revenue % change YoY	$85.75M N/A	$61.8M -27.93%	$6.51M -89.46%	Avg: $38M Low: $38M High: $38M avg. 483.43%	Avg: $50.6M Low: $50.6M High: $50.6M avg. 33.15%
Net Income % change YoY	$-114.31M N/A	$-59.24M 48.17%	$23.91M 140.36%	Avg: $-2.59M Low: $-2.59M High: $-2.59M avg. -110.83%	Avg: $0 Low: $0 High: $0 avg. 100%
EBITDA % change YoY	$-63M N/A	$-34.60M 45.06%	$26.30M 176.02%	Avg: $-31.49M Low: $-31.49M High: $-31.49M avg. -219.71%	Avg: $-41.93M Low: $-41.93M High: $-41.93M avg. -33.15%
EPS % change YoY	-$98.27 N/A	-$38.27 61.05%	$3.69 109.64%	Avg: -$0.4 Low: -$0.4 High: -$0.4 avg. -110.84%	Avg: $0 Low: $0 High: $0 avg. 100%
Operating Expenses % change YoY	$117.48M N/A	$71.30M -39.30%	$-9.56M -113.40%	Avg: $96.55M Low: $96.55M High: $96.55M avg. 1109.89%	Avg: $128.57M Low: $128.57M High: $128.57M avg. 33.15%

FAQ

Wall Street analysts estimate the annual average earnings growth rate of -55.41% in 2025-2026.

We have gathered data from N/A analysts. Their low estimate is -2.59M, average is -2.59M and high is -2.59M.

Wall Street analysts forecast annual average revenue growth of 258.29% in 2025-2026.

We have gathered data from 1 analysts. Their low revenue estimate is $38M, average is $38M and high is $38M.

Wall Street analysts forecast annual average earnings growth of -55.42% in 2025-2026.

We have gathered data from N/A analysts. Their low earnings per share estimate is -$0.4, average is -$0.4 and high is $-0.4.